Objective: We have previously shown (Hunziker and Rosenberg, J Bone Joint Surg 1996;78A:721-33) that synovial cells can be induced to migrate into partial-thickness articular cartilage defects, therein to proliferate and subsequently to deposit a scar-like tissue. We now wished to ascertain whether these synovial cells could be stimulated to transform into chondrocytes, and thus to lay down cartilage tissue, by the timely introduction of a differentiation factor.
Introduction
The appearance of discrete structural lesions within the substance of mature articular cartilage tissue represents one of the earliest overt signs of osteoarthritis (OA). That such lesions fail to heal spontaneously 1 -and consequently undergo inexorable enlargement with timeaccounts for the progressive nature of OA and for its development into the debilitating condition that it ultimately becomes. [2] [3] [4] This intrinsic incapacity of articular cartilage lesions to undergo spontaneous repair has been variously interpreted. The most popular conception is that such lesions, being walled off from the underlying bone-marrow and blood-vascular spaces, are not accessible to these sources of potential repair cells. [5] [6] [7] [8] [9] However, we have recently shown that cells from the synovial membrane and subsynovial space can be locally stimulated to migrate into the defect void. 1, 10 When appropriate measures are taken to furnish the lesion with a space-filling matrix containing the necessary chemotactic/mitotic factor, these mesenchymal-like cells can be induced to populate it and subsequently to lay down a primitive type of scar tissue. This tissue endures, but fails to transform into cartilage. 1 The need for introducing a tissue differentiation factor into this system thus became evident. Transforming growth factor-1 (TGF-1) represents one of the most suitable candidates, since it is well known to induce the formation of cartilage tissue. [11] [12] [13] [14] [15] [16] However, this substance needs to be applied at a relatively high concentration to be effective in its differentiation capacity. And since several authors 17, 18 have shown that the free injection (or infusion) of TGF-1 into the joint cavity precipitates severe adverse effects, such as inflammatory joint disease, cartilage destruction and osteophyte formation, great care must be exercised in its use. From these as well as from our own studies, 1 it has become evident that this agent must be introduced directly into the defect void and its sphere of influence confined to this site. Moreover, the actual time of its application (or release) needs to be well coordinated with the processes set in train by the chemotactic/mitogenic factor, such that the necessary signal for remodeling does not come before the synovial cells have laid down their mesenchymal-like tissue. It was the aim of the present study to test whether this end could be achieved by incorporating liposomeencapsulated TGF-1, together with the free chemotactic/ mitogenic factor, into the space-filling matrix.
Histological, histochemical and immunohistochemical analyses were undertaken to evaluate the nature of the tissue formed during the course of 1 year, and measures taken to assess its compositional stability and integration with vicinal native cartilage.
anesthetized by intravenous injection of Vetalar ® (ketamine hydrochloride) in combination with Halothan ® (2-bromo-2-chloro-1,1,1-trifluoraethane) and nitrous oxide (by intubation). Parapatellar medial arthrotomies were performed simultaneously on both knee joints. Following exposure of the femoral groove and the medial femoral condyle, superficial defects were created using a custom-built planing instrument (Rolf Haenggi-Engineering AG, Grenchen, Switzerland). 1, 10, 19 One proximal and one distal defect were created on each facet of the patellar groove of the femur and another on the medial femoral condyle (i.e. a total of five defects per knee joint, each of which was 0.5 mm in depth, 0.5 mm in width and 8-10 mm in length).
Defects in the 20 experimental animals (see Group I in Table I ) were dried and then filled with an aqueous solution of chondroitinase AC (1 unit/ml) to remove cartilage matrix glycosaminoglycans (proteoglycans) along the lesion surface, thereby exposing the underlying collagenous network. This step was undertaken to facilitate adherence of the applied matrix to the defect walls, 19, 20 with the ultimate aim of improving the structural integration between repair and native tissue. The enzyme solution was removed by blotting with a sterile sponge after 4-5 min, the defect being then thoroughly rinsed with physiological sodium chloride solution and again blotted dry. Fibrinogen solution (19 mg/ ml of 0.15 M Tris-buffered saline) containing free (4 ng/ml) and liposome-encapsulated (600 ng/ml) TGF-1, was then deposited to bulging point within the void of each lesion, approximately 2-4 l being required for this purpose. Approximately 0.5-1 l of a thrombin solution (1 unit/ml of 0.15 M Tris-buffered saline) was then applied to the surface of the fibrinogen solution, through which it permeated and promoted polymerization and clotting in situ. The final concentrations of fibrinogen and thrombin were estimated to lie within ±25% of the original ones.
Defects in the other 27 animals served as controls; details of their treatment are summarized in Table I .
The wounds were closed and animals permitted free joint movement immediately after recovery from the operation. At the end of the follow-up period (2, 4, 6 or 12 months; see Table I ), miniature pigs were again anesthetized and then killed by administering an overdose of potassium chloride to induce cardiac arrest. Fibrinogen was purified from the blood of either young adult cows or Goettingen miniature pigs according to the procedure described by Mosher et al. 21 Purified fibrinogen solutions were employed at a final concentration of 19 mg/ ml of 0.15 M Tris-buffered saline. Fibrinogen polymerization was induced by the addition of bovine thrombin, the commercial product (10 units/ml) being diluted 1:10 immediately prior to use. A gelatine matrix (160 mg/ml of Tris-buffered saline) and a gelatine/fibrin copolymer were also prepared, the latter being generated by the addition of 160 mg of gelatine powder to 1 ml of the purified fibrinogen solution described above.
Purified, freeze-dried TGF-1 (of porcine platelet origin) was dissolved, according to the manufacturer's specifications (in 4 mM sterile hydrochloric acid containing 0.1% bovine serum albumin), immediately prior to use, and employed either in free suspension at 4 ng/ml, or in a liposome-encapsulated form. TGF-1 was encapsulated within liposomes according to the standard procedure described by Kim et al. 22 Liposomes were prepared by the evaporation of organic solvents from chloroform-ether spherules suspended in water. Each spherule contained numerous water droplets holding the solute to be trapped upon solvent evaporation. The incorporation rate was estimated (using I 125 -labeled TGF-1) to be 75%. Liposome particles were utilized at a final concentration for TGF-1 of 600 ng/ml of fibrinogen solution. The retention rates of free and liposome-encapsulated TGF-1 by fibrin matrices were also monitored over a period of 25 days at 37°C in vitro using I 125 -labeled TGF-1. The daily release rate of liposome-encapsulated TGF-1 was steady at 2-3%, 73% of this agent being still present within the fibrin matrix after 10 days; by the end of the 25th day, 47% of the liposomeencapsulated TGF-1 had been retained. In contrast, the rate of loss of non-encapsulated TGF-1 was fairly high during the first few days of monitoring (between 15 and 20%), decreasing steadily thereafter to lower levels. By the end of the 25th day, only 12% of the free agent had been retained by the fibrin matrix (unpublished data).
Free insulin-like growth factor (IGF-1) and free basic fibroblast growth factor (bFGF) were dissolved in 0.15 M Tris-buffered saline to yield final concentrations of 40 and 10 ng/ml, respectively. TISSUE PROCESSING Distal femurs were removed immediately after the death of animals and, unless otherwise specified (cf. immunohistochemical analyses), sawed into three pieces (medial condyle; upper and lower halves of patellar groove) using an Exakt ® diamond saw. Tissue blocks were chemically fixed for light microscopic analysis in a solution containing glutaraldehyde and formaldehyde, both at a concentration of 2.5% in 0.1 M sodium cacodylate buffer (pH 7.4), for 4-6 days at ambient temperature. They were then dehydrated in a graded series of increasing ethanol concentration and embedded in methyl methacrylate. Serial cuts through blocks were produced perpendicular to the defect axis using a Leco ® diamond saw (Leco Corporation, St. Joseph, U.S.A.). They were then glued onto polished plexiglas object holders, milled to a thickness of approximately 80-150 m with a Reichert Polycut E apparatus (ReichertJung, Nussloch, Germany), polished and surface-stained with McNeil's Tetrachrome/Toluidine Blue 0/basic Fuchsine.
For analyses in the polarization microscope (Olympus Vanox AH2), a selection of tissue cuts (80-120 m in thickness) was prepared.
For immunohistochemical analyses, 1.3-mm-thick tissue slices were prepared from native material using a diamond saw. These were then mounted on a specimen holder using Tissue Tek ® and frozen with carbon dioxide. 20-m-thick cryosections were produced in a Linde-cryostat using a Jung stainless steel microtome. Sections were air-dried and maintained in a frozen condition at −30°C until required for immunostaining.
Immunostaining with horseradish-peroxidase-labeled antibodies was carried out according to standard protocols. 23 For positive controls, normal articular cartilage tissue (neighboring the defect site) was utilized. Negative controls were prepared by applying antibodies against artificial epitopes (a polyclonal anti-dansyl antibody and a monoclonal antibody against chrome-pure epitopes). Antibodies against collagen types I and II, the hyaluronic-acidbinding region of proteoglycans, cartilage oligomeric matrix protein and epitopes along glycosaminoglycan chains were employed to characterize the repair tissue.
Prior to the immunostaining procedure, cryosections were fixed in cold acetone, washed, treated with 1% hydrogen peroxide (in methanol), again washed, incubated with chondroitinase AC (40 milliunits/ml) for 60 min, washed, and then exposed to 1% bovine serum albumin (in 0.05 M Tris-phosphate buffer) for 30 min. After further rinsing, the primary antibody was then applied at dilutions of 1:50 and 1:200. After incubation for 1 h at ambient temperature, sections were washed and then treated with the peroxidase-labeled secondary antibodies (1:50 and 1:200) for 45 min. 23 
TISSUE ANALYSIS
For routine histological and morphometrical analyses using the light microscope, one large tissue block was prepared from either the femoral groove or condyle; it contained all of the lesions created in the relevant region. Thick sections derived from each of the defects were assessed. One tissue block from one animal per time point was subjected to immunohistochemical analysis.
The degree of cell and tissue differentiation was quantified using three randomly-selected sections derived from a series of eight to twelve along the entire defect length. Tissue was defined as being 'differentiated and cartilagelike' if cells exhibited a chondrocyte-like phenotype (rounded form; surrounded by a lacuna) and if the matrix manifested a cartilage-like organization. Areas in which cells remained spindle-like (mesenchymal) and in which the matrix remained predominantly fibrous in nature were classified as being 'non-differentiated'; intermediate states of tissue differentiation were assigned to this latter category. In all sections analyzed, the percentage of the area transformed to cartilage-like tissue was estimated in steps of 25% [i.e. less than 25%, between 26 and 50%, between 51 and 75% and more than 75% (see Table II) ].
The staining intensity of the repaired cartilage matrix was used as an index of its proteoglycan content. It was graded semi-quantitatively by a blinded observer from 0 (purely fibrous matrix) to + + + (intensity equivalent to that manifested by normal native cartilage matrix). The number of defects analyzed was the same as that used to estimate tissue-transformation processes (see above). 
Results
The repair tissue formed in the experimental group of animals (Group I in Table I ) bore a close resemblance to cartilage [ Fig. 1(C) -(H); Fig. 2 ]: cells manifested a chondrocyte-like phenotype and were embedded within a matrix which evinced the histochemical staining characteristics of cartilage. As may be seen from Table II , the degree of cell (tissue) differentiation was variable; but by 12 months, tissue within 54% of the defects had undergone transformation to the extent of 75% or more. Temporal differences in the percentage of defects manifesting a given degree of tissue transformation probably reflect a broad range of variation in the result achieved (which is typical for cartilage repair studies) rather than de-and redifferentiation effects. Detailed morphological analyses revealed that deeper regions-corresponding to the level of the radial zone in adjacent native cartilage-transformed more frequently than did more superficial ones-corresponding to the level of the tangential zone in adjacent native cartilage.
The histochemical staining for proteoglycans within repair tissue varied considerably in intensity (see Table III ). Most sections manifested a degree intermediate between that evinced in fibrous connective tissue (0) and normal articular cartilage matrix (+ + +). Immunohistochemical analyses of selected defects confirmed these findings, and further revealed that some of the cartilage-specific epitopes (i.e. the hyaluronic-acid-binding region for proteoglycans, type II collagen fibrils, cartilage oligomeric matrix protein and chondrotin-sulfate-specific sites for proteoglycanglycosaminoglycan chains) were indeed expressed in this repair tissue (Fig. 3) . But epitopes for fibrillar type I collagen were also present, and these persisted throughout the entire follow-up course. Polarization microscopy disclosed collagen fibrils to be more isotropically organized than in normal articular cartilage [ Fig. 2] .
Chondrocyte-like cells in the repair tissue did not adopt the perfect anisotropic pattern of organization manifested in normal articular cartilage, but a structural differentiation gradient was nonetheless apparent: cells closest to the defect surface tended to be more spindle-like than those in deeper regions [see Fig. 1(C) ]. The latter were distributed more isotropically, and were usually present at higher numerical densities, than in normal articular cartilage, although this was not always the case [see Fig. 1(H) ]. Albeit so, they tended to adopt the size and shape characteristics of cells in the physiological hypertrophic zone, and they retained these conformations up to the end of the 1-year observation period. Repair and native tissue compartments were generally well integrated [ Fig. 1(D) -(H); Fig. 2; Fig. 3 ], although clefts were apparent in some locations [ Fig. 1(C) ]. Polarization microscopy confirmed the existence of good tissue integration in cleft-free regions [ Fig. 2(B) ].
During the course of its polymerization, clotting and stabilization, fibrin typically retracts. 24, 25 It was thus not surprising that the matrices composed of this material frequently, and to a variable degree, shrunk away from the free defect surface. This phenomenon probably accounts for the frequently concave contour of the repair-tissue surface relative to that of the native articular cartilage [see Fig. 1 
(C),(E)].
In the untreated group of miniature pigs (Group II in Table I ), a few mesenchymal-like cells were apparent along the defect borders, and a limited degree of chondrocyte proliferation was to be seen within vicinal native tissue, 1 but no repair tissue of any description was laid down at any time during the 1-year follow-up period [ Fig. 1(B) ].
In defects treated with chondroitinase AC, free TGF-1 (4 ng/ml), a fibrin matrix and EMPTY liposomes (Group III in Table I ), a mesenchymal type of repair tissue was laid down, as previously reported. 1 There was no evidence of transformation into cartilage-like tissue. Hence, liposomes, per se, do not have any differentiation activity.
In defects treated first with chondroitinase AC and then with an EMPTY fibrin matrix (Group IV in Table I ), the clots were sparsely populated with mesenchymal-like cells, which had partially remodeled the fibrin and in its place had laid down a tenuous mesenchymal-like connective tissue. 1 Defects that received a gelatine matrix (Group V in Table I ) or a gelatine fibrin-copolymer (Group VI in Table I ), but in all other respects were treated similarly to the experimental group of animals, were filled with a cartilagelike repair tissue which was indistinguishable from that laid 
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down in the presence of a fibrin matrix, thus ruling out a fibrin-specific effect. Substitution of miniature-pig-derived fibrinogen for bovine-derived fibrinogen (Group X in Table I) in the experimental protocol did not influence the repair result. When free IGF-1 (Group VII in Table I ) or free bFGF (Group VIII) were substituted for free TGF-1 in the experimental protocol, essentially the same repair response was elicited in each case, with the exception that the cellularity of the cartilage-like tissue formed in these substitute cases was somewhat lower than in the presence of free TGF-1.
Omission of free TGF-1 from the experimental protocol (Group IX in Table I ) yielded a repair result that differed from that elicited in its presence in only one respect: the cellularity of the cartilage-like tissue formed was somewhat lower.
Discussion
In the forerunner 1 to the present investigation, we demonstrated that when partial-thickness defects within mature articular cartilage are filled with a space-defining fibrin matrix containing a free chemotactic/mitogenic factor, cells for the repair process can be stimulated to migrate from the synovium, to populate the matrix scaffold, and therein to undertake its remodeling into a primitive type of connective tissue. Although this scar-like tissue endured, it failed to transform into cartilage. It was the aim of the present investigation to elicit this tissue transformation by introducing a liposome-encapsulated chondrogenic differentiation factor into the fibrin matrix along with the free chemotactic/mitogenic one. We hoped that this tissue Superficial defects 2 months after treatment with chondroitinase AC and application of a fibrin matrix containing both free (4 ng/ml) and liposome-encapsulated (600 ng/ml) TGF-1. Each defect (D) is filled with repair tissue which has a cartilage-like appearance. Cells have undergone transformation into chondrocyte-like ones, but are more isotropically distributed and present at a higher numerical density than those within the surrounding native tissue. A gradient in cell size and shape is nonetheless apparent, chondrocytes in superficial regions being small and spindle-like (SLC), those in deeper ones being larger and having an oblate spheroid form (OSC). Chondrocyte-like cells have laid down a matrix which stains somewhat less homogeneously than that of native tissue, which circumstance indicates that it is not truely hyaline, but rather fibrous, in nature. At the defect borders (DB), repair and native tissue are well integrated except at the upper-right and lower-left corners (CL) in (C). (E), (F) Superficial defects (D) 6 months after the treatment described above. Contiguity between repair and native tissue (DB) has been maintained, but chondrocytes are still more isotropically distributed and present at a higher numerical density than those in the vicinal native cartilage. These two examples illustrate well the paler-than-normal staining properties of the intercellular matrix, this circumstance being indicative of its lower progeoglycan content. (G), (H) Superficial defects (D) 12 months after instigation of the treatment protocol described above. The situation is comparable to that manifested at 6 months, i.e. tissue has undergone no further differentiation during the interim. However, the very stability of repair tissue at this stage is by no means a trivial circumstance. Osteoarthritis and Cartilage Vol. 9 No. 1 27 Fig. 3 . 28 E. B. Hunziker: Partial-thickness defects in adult articular cartilage transformation factor would be released at the time when matrix remodeling was well under way, thereby optimizing the differentiation of primitive into cartilage-like tissue. Our treatment principle thus aimed at the sequential stimulation of articular cartilage's intrinsic repair potential by use of appropriate growth factors delivered at the critical junctures. On the basis of this rationale, we were able to induce the repair of partial-thickness defects in mature articular cartilage. The beauty of such a treatment principle is that it culls the tissue's natural resources, thereby obviating the need for cell or tissue transplantation (with the potential risk of inducing adverse immunological reactions), and can be instigated during a single surgical intervention. The histological, histochemical, immunohistochemical and polarization microscopic characterization of the repair tissue clearly revealed it to be cartilage-like in nature. All the functionally-important cartilage matrix components [26] [27] [28] [29] [30] [31] were present in appreciable quantities. That the repair tissue endured throughout the course of the entire follow-up period, i.e. 1 year, is strongly supportive of its being compositionally stable. However, the persistence of type I collagen, a component not typically present in hyaline cartilage matrix, as well as the relatively low proteoglycan content, suggest that its composition, and hence also its functional competence, were not optimal. Similar problems have been experienced hitherto in all types of cartilagerepair concepts (for reviews, see 10, [32] [33] [34] [35] ). It remains to be clarified whether the type I collagen encountered is indeed merely a remnant of the scar-like tissue initially laid down or whether this material continues to be produced even after differentiation processes have begun (as occurs in fibrous cartilage). Given the long half-life of fibrillar collagen in skeletal tissues, [36] [37] [38] the former possibility seems likely. Whatever the case, the persistence of type I collagen will undoubtedly influence the properties of the repair tissue formed. Mechanical testing of such small lesions as those described here is, however, not practicable; a much larger superficial-defect model would be required for such purposes.
The presence of cartilage-specific matrix components (such as cartilage oligomeric matrix protein, 31 type II collagen [28] [29] [30] and aggrecan 30 ) in the repair tissue argues favorably for a relatively high degree of tissue transformation, as does the existence of chondrocyte-like cells manifesting different degrees of morphological differentiation. The predominance of spindle-like cells in superficial regions and of large hypertrophic ones in deeper zones accords well with the physiological situation. 39, 40 A clearcut gradient and perfectly columnar arrangement of cells was, however, not achieved, and cellularity was generally too high. Further improvements in the architectural result could possibly be achieved by the introduction of substances known to influence cartilage maintenance (e.g. insulin-like growth factor II).
One of the great assets of our proposed treatment protocol is that cells for the repair process are recruited from joint-specific tissue sources.
1 During fetal development, joints in different topographical regions of the skeleton adopt the shapes and structures commensurate with their biomechanical and biochemical needs, which can vary considerably. Since synovial-joint tissues differentiate from locally-specific mesenchymal cells, the recruitment of these latter for the purposes of local repair would appear to be ideal. [41] [42] [43] [44] Interfacial integration between repair tissue and native cartilage was generally good, as revealed by polarization microscopy. This is an aspect of considerable practical importance, since any clefts existing in the interfacial region represent potential sites for tissue degradation by proteases present within the synovial fluid. 45, 46 The physiological effects and biological activities of differentiation factors are influenced not only by the cell types involved, and their microenvironment, but also by the concentrations of these agents. 47 In vitro, TGF-1 has been shown to act in the capacity of a chemotactic and/or mitogenic agent at low activities (0.1-10 ng/ml), whereas at higher ones (>100 ng/ml), these effects are reversed and chemotaxis may even be inhibited. 12, [48] [49] [50] [51] [52] [53] [54] Moreover, at these high activities, this substance is known to promote tissue transformation or differentiation. 12, 15, 48, 50 Hence, the precise control of growth-factor concentration in clinically-applied systems is of fundamental importance.
In a preliminary investigation (data not presented), TGF-1 was shown to act in its chondrogenic differentiation capacity over the range 100-1500 ng/ml, with no adverse consequences. However, there is a limit to which one can go in this respect, since the leakage of very high concentrations into the joint cavity could lead to synovitis, pannus or osteophyte formation and cartilage degradation. 17, 18, 55 For this reason, use of the minimal effective concentration is advisable. To be on the safe side, we chose one of 600 ng/ml.
The mechanism whereby the encapsulated differentiation factor is released in vivo can only be speculated upon at present. One possibility is that the liposomes are themselves phagocytozed by the synovial cells, within which they are degraded and the TGF-1 thereby liberated, perhaps to act via an intracellular signaling pathway (as reported for bFGF 56 ). Alternatively, liposomes could be degraded within the extracellular space, and the released TGF-1 induce cell differentiation processes via plasmalemmal receptors. 57, 58 Both possibilities are indeed feasible, since TGF-1 is known to be capable of stimulating cell activities from both intra-and extracellular sites. [57] [58] [59] The important point to bear in mind is that the concentration-specific effects of TGF-1 as either a mitogenic/chemotactic factor (at low activity) or a differentiation one (at high activity) require the sequential application of this substance (at the required activity levels) in order to induce the desired effects at the appropriate points in time. The release of liposome-encapsulated TGF-1 at a stage when synovial cells have already invaded the fibrin matrix and begun to remodel it, represents an elegant internal timing mechanism mediated by the repair cells themselves. Other sequestering systems are available (e.g. gelatinemicrospheres, 60 polylactic-glycoside capsules 61 and fibrilassociated delivery [62] [63] [64] , and any of these could, in principle, be considered as alternatives to the liposomeencapsulation mode adopted by ourselves.
The synovial cells involved in this repair process appear to have a very limited perception of space, and an artificial matrix is thus required as a guide to define the defect void. 1 Moreover, the porosity of this matrix needs to be such that these cells can grow into and populate it. 65 A biodegradable material (such as fibrin, gelatine or collagen, or copolymers of these) is preferable, since the mechanical and chemical properties of non-biodegradable ones change with time, and some degradation-or release products generated over longer periods may have local toxic effects. The fibrin matrix used by ourselves served as a starting point for establishing the principles of repair induction in partialthickness articular cartilage defects; but it is clearly not the ideal choice for clinical purposes, owing to the clotretraction problem which leads to incomplete filling of the defect space.
Variations in the degree to which tissue transformation takes place stem not only from problems with the matrix, but also from those associated with the preparation of liposomes. The method employed 22 yields particles spanning a fairly broad size-range [from less than 1 m up to 15 m in diameter (determined by electron microscopy; data not presented)]. If we could secure a more uniform size distribution, as well as improve the mixing process with the matrix (to obtain a more even distribution of particles), then two sources of variability would be eliminated. We have, in fact, recently tested a population of polylactate microspheres for TGF-1 incorporation and delivery, which has a very homogeneous particle size (<1 m in diameter). Preliminary testing with such suspensions has yielded reproducibly complete tissue-transformation results (data not presented).
Our system is clearly not yet ready for clinical use; but then, it was not the purpose of this study to realize this end, but rather to delineate the working principles of a protocol whereby healing of partial-thickness defects in mature articular cartilage could be induced by culling the tissue's own natural resources. Indeed, the results achieved at this stage are far better than our most sanguine expectations.
